- Large homogenous population
- High prevalence of communicable diseases
- Efficient regulatory system
- Low operational cost
Thailand with a population of 69.6 million, offers universal healthcare to its citizens, but despite ongoing improvements, communicable diseases remain a serious public health issue, especially in regional areas. HIV/AIDS has an increasing prevalence (1.5% of all persons aged 15-49 years).
Thailand is characterized by good regulatory and ethical standards, internationally trained doctors and medical personnel, and Government support for medical research industry.
With a high prevalence of communicable diseases and liver diseases (HIV, Hepatitis), biotechnology companies are increasingly looking at Thailand for their clinical trials.
Thailand offers high-quality sites, lower costs and lower trial density than Western countries.
High prevalence diseases include:
- Infectious diseases
- Heart disease.
Novotech estimates the clinical activity growth of biotechnology companies in Thailand to have to have doubled in recent years.
Novotech has established strong clinical teams in Thailand with deep local knowledge to deliver quality CRO services to biotechnology companies.
In addition, it has partnered with key specialist hospital and research facilities including King Chulalongkorn Hospital and the Srinagarind Hospital as part of its Partner Program. This gives Novotech clients direct access to the most active and reputable KOLs, PIs and sites to facilitate study start-up and patient recruitment.